Skip to content
2000
image of Evidence of the Efficacy of Acetylcholinesterase Inhibitors in In Vivo Studies: A Systematic Review

Abstract

Introduction

This systematic review aimed to provide an updated overview of studies using anticholinesterases with activity for the treatment of Alzheimer's disease.

Methods

A systematic review was conducted using searches in the following databases: PubMed, SciELO (Scientific Electronic Library Online), Web of Science, LILACS (Latin American and Caribbean Literature in Health Sciences), as well as gray literature, through the CAPES and Google Scholar databases of national and international journals. The research was registered on the International Prospective Register of Systematic Reviews (PROSPERO) platform under registration number: CRD42024482117 and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol.

Results

A total of 1,191 articles were identified in the databases, of which 11 were selected to compose this systematic review, as they met the previously pre-defined selection criteria. The selected articles were published between 2019 and 2023. The substance most commonly used to induce Alzheimer's was scopolamine. As for administration routes, the most used was intraperitoneal. Some of the methods used to evaluate cognitive processes in rats and mice were— Elevated Plus Maze (EPM), Morris water maze (MWZ), Y maze, and passive avoidance tests.

Discussion

The reviewed studies demonstrated that the evaluated anticholinesterase agents 
exhibited anti-Alzheimer activity in animal models, with notable cognitive effects observed in behavioral tests.

Conclusion

The data indicated that the analyzed anticholinesterase agents have therapeutic potential for Alzheimer's disease, justifying the continuation of preclinical research and future clinical investigations.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273388078250801044226
2025-08-18
2025-12-08

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273388078250801044226
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Rabbito A. Dulewicz M. Kulczyńska-Przybik A. Mroczko B. Biochemical markers in alzheimer’s disease. Int. J. Mol. Sci. 2020 21 6 1989 10.3390/ijms21061989 32183332
    [Google Scholar]
  2. Kumar A. Singh A. Ekavali. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015 67 2 195 203 10.1016/j.pharep.2014.09.004 25712639
    [Google Scholar]
  3. Bhute S. Sarmah D. Datta A. Molecular pathogenesis and interventional strategies for Alzheimer’s disease: Promises and pitfalls. ACS Pharmacol. Transl. Sci. 2020 3 3 472 488 10.1021/acsptsci.9b00104 32566913
    [Google Scholar]
  4. Hampel H. Mesulam M.M. Cuello A.C. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 2018 141 7 1917 1933 10.1093/brain/awy132 29850777
    [Google Scholar]
  5. Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol. Med. Rep. 2019 20 2 1479 1487 31257471
    [Google Scholar]
  6. Andrade A.M. Teixeira V.R. Pogue R. Figueiredo A.C.M.G. Carvalho J.L. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults. Cytotherapy 2023 25 9 930 938 10.1016/j.jcyt.2023.05.011 37341664
    [Google Scholar]
  7. Hooijmans C.R. Rovers M.M. de Vries R.B.M. Leenaars M. Ritskes-Hoitinga M. Langendam M.W. SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol. 2014 14 1 43 10.1186/1471‑2288‑14‑43 24667063
    [Google Scholar]
  8. Ezzat M.A.F. Abdelhamid S.M. Fouad M.A. Abdel-Aziz H.A. Allam H.A. Design, synthesis, in vitro, and in vivo evaluation of novel phthalazinone‐based derivatives as promising acetylcholinesterase inhibitors for treatment of Alzheimer’s disease. Drug Dev. Res. 2023 84 6 1231 1246 10.1002/ddr.22082 37243322
    [Google Scholar]
  9. Kamel N.N. Aly H.F. Fouad G.I. Anti-Alzheimer activity of new coumarin-based derivatives targeting acetylcholinesterase inhibition. RSC Advances 2023 13 27 18496 18510 10.1039/D3RA02344C 37346948
    [Google Scholar]
  10. Patel V.C. Samresh P.R. Dipayan T. Nidhi C. Investigation into anti-alzheimer activity of newly developed phthalimide derivatives in experimental animals. Pharm. Chem. J. 2023 57 1 60 69 10.1007/s11094‑023‑02851‑y
    [Google Scholar]
  11. Singh V. Kaur K. Kaur S. Shri R. Singh T.G. Singh M. Trimethoxyflavones from Ocimum basilicum L. leaves improve long term memory in mice by modulating multiple pathways. J. Ethnopharmacol. 2022 295 115438 10.1016/j.jep.2022.115438 35671863
    [Google Scholar]
  12. Amin K.M. Abdel Rahman D.E. Abdelrasheed Allam H. El-Zoheiry H.H. Design and synthesis of novel coumarin derivatives as potential acetylcholinesterase inhibitors for Alzheimer’s disease. Bioorg. Chem. 2021 110 104792 10.1016/j.bioorg.2021.104792 33799178
    [Google Scholar]
  13. Randhawa K. Singh V. Kaur S. Kaur R. Kumar S. Shri R. Isolation of Pleurotus florida derived acetylcholinesterase inhibitor for the treatment of cognitive dysfunction in mice. Food Sci. Hum. Wellness 2021 10 4 490 496 10.1016/j.fshw.2021.04.011
    [Google Scholar]
  14. El-Hawary S.S. Sobeh M. Badr W.K. HPLC-PDA-MS/MS profiling of secondary metabolites from Opuntia ficus-indica cladode, peel and fruit pulp extracts and their antioxidant, neuroprotective effect in rats with aluminum chloride induced neurotoxicity. Saudi J. Biol. Sci. 2020 27 10 2829 2838 10.1016/j.sjbs.2020.07.003 32994743
    [Google Scholar]
  15. Gupta M. Ojha M. Yadav D. Pant S. Yadav R. Novel Benzylated (Pyrrolidin-2-one)/(Imidazolidin-2-one) derivatives as potential anti-alzheimer’s agents: synthesis and pharmacological investigations. ACS Chem. Neurosci. 2020 11 18 2849 2860 10.1021/acschemneuro.0c00403 32816447
    [Google Scholar]
  16. Hoang T.H.X. Ho D.V. Van Phan K. Le Q.V. Raal A. Nguyen H.T. Effects of Hippeastrum reticulatum on memory, spatial learning and object recognition in a scopolamine-induced animal model of Alzheimer’s disease. Pharm. Biol. 2020 58 1 1107 1113 10.1080/13880209.2020.1841810 33170051
    [Google Scholar]
  17. Song X. Wang T. Guo L. In vitroand in vivo anti-AChE and antioxidative effects of schisandra chinensis extract: A potential candidate for Alzheimer’s disease. Evid. Based Complement. Alternat. Med. 2020 2020 1 2804849 10.1155/2020/2804849 32148536
    [Google Scholar]
  18. Ciprés-Flores F.J. Farfán-García E.D. Andrade-Jorge E. Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory. Drug Dev. Res. 2020 81 2 256 266 10.1002/ddr.21633 31875337
    [Google Scholar]
  19. Breijyeh Z. Karaman R. Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules 2020 25 24 5789 10.3390/molecules25245789 33302541
    [Google Scholar]
  20. Lauretti E. Dincer O. Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim. Biophys. Acta Mol. Cell Res. 2020 1867 5 118664 10.1016/j.bbamcr.2020.118664 32006534
    [Google Scholar]
  21. Facchinetti R. Valenza M. Bronzuoli M.R. Looking for a treatment for the early stage of Alzheimer’s disease: Preclinical evidence with co-ultramicronized palmitoylethanolamide and luteolin. Int. J. Mol. Sci. 2020 21 11 3802 10.3390/ijms21113802 32471239
    [Google Scholar]
  22. Chen Z.R. Huang J.B. Yang S.L. Hong F.F. Role of cholinergic signaling in Alzheimer’s disease. Molecules 2022 27 6 1816 10.3390/molecules27061816 35335180
    [Google Scholar]
  23. Tang K.S. The cellular and molecular processes associated with scopolamine-induced memory deficit: A model of Alzheimer’s biomarkers. Life Sci. 2019 233 116695 10.1016/j.lfs.2019.116695 31351082
    [Google Scholar]
  24. Dhapola R. Kumari S. Sharma P. HariKrishnaReddy D. Insight into the emerging and common experimental in-vivo models of Alzheimer’s disease. Lab. Anim. Res. 2023 39 1 33 10.1186/s42826‑023‑00184‑1 38082453
    [Google Scholar]
  25. Karim N. Khan I. Khan I. Antiamnesic effects of novel phthalimide derivatives in scopolamine-induced memory impairment in mice: A useful therapy for Alzheimer’s disease. ACS Omega 2023 8 8 8052 8065 10.1021/acsomega.2c07951 36872974
    [Google Scholar]
  26. Wang D. Hu M. Li X. Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2019 168 207 220 10.1016/j.ejmech.2019.02.053 30822710
    [Google Scholar]
  27. Yamali C. Ozan Gülcan H. Kahya B. Çobanoğlu S. Şüküroğlu M.K. Doğruer D.S. Synthesis of some 3(2H)-pyridazinone and 1(2H)-phthalazinone derivatives incorporating aminothiazole moiety and investigation of their antioxidant, acetylcholinesterase, and butyrylcholinesterase inhibitory activities. Med. Chem. Res. 2015 24 3 1210 1217 10.1007/s00044‑014‑1205‑8
    [Google Scholar]
  28. Azimi S. Zonouzi A. Firuzi O. Discovery of imidazopyridines containing isoindoline-1,3-dione framework as a new class of BACE1 inhibitors: Design, synthesis and SAR analysis. Eur. J. Med. Chem. 2017 138 729 737 10.1016/j.ejmech.2017.06.040 28728105
    [Google Scholar]
  29. Kurt B.Z. Gazioglu I. Sonmez F. Kucukislamoglu M. Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives. Bioorg. Chem. 2015 59 80 90 10.1016/j.bioorg.2015.02.002 25706320
    [Google Scholar]
  30. Ghanei-Nasab S. Khoobi M. Hadizadeh F. Synthesis and anticholinesterase activity of coumarin-3-carboxamides bearing tryptamine moiety. Eur. J. Med. Chem. 2016 121 40 46 10.1016/j.ejmech.2016.05.014 27214510
    [Google Scholar]
  31. Ciprés-Flores F.J. Segura-Uribe J.J. Orozco-Suárez S. Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampus. Life Sci. 2019 224 128 137 10.1016/j.lfs.2019.03.043 30905783
    [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273388078250801044226
Loading
Evidence of the Efficacy of Acetylcholinesterase Inhibitors in In Vivo Studies: A Systematic Review
Bentham Science Publishers ; https://doi.org/10.2174/0118715273388078250801044226
/content/journals/cnsnddt/10.2174/0118715273388078250801044226
/content/journals/cnsnddt/10.2174/0118715273388078250801044226
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: Alzheimer's disease ; cholinesterase inhibition ; systematic review ; anticholinesterase agents ; in vivo studies ; Acetylcholinesterase inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test